Latest Strategy News

Stavely Minerals has unveiled a substantial upgrade to its 2026 Mineral Resource Estimate, more than doubling contained copper and advancing a scoping study that highlights promising production potential.

Worley has received the Full Notice to Proceed from Venture Global for Phase 2 of the CP2 LNG export project in Louisiana, marking a significant milestone following Venture Global’s Final Investment Decision.

TMK Energy has raised $6 million in a heavily oversubscribed placement led by coal seam gas experts, aiming to accelerate drilling and commercialisation at its Gurvantes XXXV project.

QX Resources has confirmed multiple high-grade uranium zones at surface within its Madaba Uranium Project in Tanzania, identifying nine immediate drill targets. Planned exploration aims to rapidly advance towards a maiden resource.

Core Lithium has successfully raised A$120 million through a two-tranche institutional placement, securing full funding to restart its Finniss Lithium Operation and target production by Q3 2026.

Image Resources NL has extended its prepayment facility term to December 2026 and negotiated a six-month repayment holiday to ease cashflow pressures amid a soft mineral sands market.

Patriot Resources has appointed Dominic Duggan as Managing Director and CEO, signalling a strategic push to advance its global mining projects. Duggan’s blend of technical and financial expertise is expected to steer the company through its critical development stage.

Lightning Minerals has appointed Troy Brice as CEO, bringing seasoned leadership to spearhead the next phase of exploration at its Mt Turner Gold Project.

EV Resources has restructured its Tecomatlán plant acquisition to fast-track antimony production with a low-risk, milestone-based payment plan. Refurbishment is underway, supported by strong metallurgical results and a clear path to near-term output.

Novo Resources has officially listed over 25 million free-attaching options on the ASX, following its recent capital raising. These options, exercisable at 15 cents, underpin the company’s ongoing exploration ambitions across Western Australia and New South Wales.

Little Green Pharma has terminated its planned sale and leaseback of its Western Australian production facility after failing to reach commercial terms, choosing to retain ownership without impacting operations.

Nexalis Therapeutics has initiated dosing in its Phase 1 trial of IRX-616a, a novel cannabidiol inhalation treatment targeting panic disorder. The trial aims to evaluate safety and pharmacokinetics, with dose escalation decisions expected soon.